A Zuddas

Summary

Affiliation: University of Cagliari
Country: Italy

Publications

  1. ncbi Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder
    Philip Hazell
    Child and Youth Mental Health Service, University of Newcastle, Locked Bag 1014, Wallsend, NSW 2287, Australia
    Eur Child Adolesc Psychiatry 15:105-10. 2006
  2. ncbi Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies
    Alessandro Zuddas
    Centre for Pharmacological Therapy in Child and Adolescent Neuropsychiatry, Department of Neuroscience B B Brodie, University of Cagliari, Italy
    Eur Neuropsychopharmacol 21:600-20. 2011
  3. ncbi Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation
    A Zuddas
    Child Neurology and Psychiatry, Department of Neuroscience, University of Cagliari, Italy
    J Child Adolesc Psychopharmacol 10:79-90. 2000
  4. ncbi 6R-Tetrahydrobiopterin induces dopamine synthesis in a human neuroblastoma cell line, LA-N-1. A cellular model of DOPA-responsive dystonia
    Alessandro Zuddas
    Child Neuropsychiatry, Department of Neuroscience, University of Cagliari, Via Ospedale 119, 09124 Cagliari, Italy
    Brain Res 943:257-62. 2002
  5. ncbi Factor structure and cultural factors of disruptive behaviour disorders symptoms in Italian children
    Alessandro Zuddas
    Child Neuropsychiatry, Department of Neuroscience, University of Cagliari, Via Ospedale 119, 09124 Cagliari, Italy
    Eur Psychiatry 21:410-8. 2006
  6. ncbi Attention-deficit/hyperactivity disorder: a neuropsychiatric disorder with childhood onset
    A Zuddas
    Child Neurology and Psychiatry, Department of Neuroscience, University of Cagliari, Italy
    Eur J Paediatr Neurol 4:53-62. 2000
  7. ncbi Teacher reports of ADHD symptoms in Italian children at the end of first grade
    Daniele Mugnaini
    A. Meyer Children's Hospital, Florence, Italy
    Eur Psychiatry 21:419-26. 2006
  8. ncbi The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles
    Robert D Oades
    Clinic for Child and Adolescent Psychiatry, University of Duisburg Essen, Germany
    Dev Sci 8:122-31. 2005
  9. ncbi A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD
    Jan K Buitelaar
    Department of Psychiatry, University Medical Center Nijmegen, 9101, 6500, HB Nijmegen, The Netherlands
    Eur Child Adolesc Psychiatry 13:249-57. 2004
  10. ncbi European clinical guidelines for hyperkinetic disorder -- first upgrade
    Eric Taylor
    Dept of Child and Adolescent Psychiatry, Institute of Psychiatry Kings College London, De Crespigny Park, London, SE5 8AF, UK
    Eur Child Adolesc Psychiatry 13:I7-30. 2004

Collaborators

Detail Information

Publications21

  1. ncbi Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder
    Philip Hazell
    Child and Youth Mental Health Service, University of Newcastle, Locked Bag 1014, Wallsend, NSW 2287, Australia
    Eur Child Adolesc Psychiatry 15:105-10. 2006
    ..To examine the influence of comorbid oppositional defiant disorder (ODD) on the relative risk (RR) of relapse during 9 months of treatment with atomoxetine for attention-deficit/hyperactivity disorder (ADHD)...
  2. ncbi Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies
    Alessandro Zuddas
    Centre for Pharmacological Therapy in Child and Adolescent Neuropsychiatry, Department of Neuroscience B B Brodie, University of Cagliari, Italy
    Eur Neuropsychopharmacol 21:600-20. 2011
    ..e. obesity and BMI, family history of diabetes or cardiovascular disorder, etc) for the single patient...
  3. ncbi Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation
    A Zuddas
    Child Neurology and Psychiatry, Department of Neuroscience, University of Cagliari, Italy
    J Child Adolesc Psychopharmacol 10:79-90. 2000
    ..The data indicate that risperidone is an effective and relatively safe drug for long term treatment of behavioral disruption in autistic children and adolescents...
  4. ncbi 6R-Tetrahydrobiopterin induces dopamine synthesis in a human neuroblastoma cell line, LA-N-1. A cellular model of DOPA-responsive dystonia
    Alessandro Zuddas
    Child Neuropsychiatry, Department of Neuroscience, University of Cagliari, Via Ospedale 119, 09124 Cagliari, Italy
    Brain Res 943:257-62. 2002
    ....
  5. ncbi Factor structure and cultural factors of disruptive behaviour disorders symptoms in Italian children
    Alessandro Zuddas
    Child Neuropsychiatry, Department of Neuroscience, University of Cagliari, Via Ospedale 119, 09124 Cagliari, Italy
    Eur Psychiatry 21:410-8. 2006
    ..The aim of the study was to verify, by factor confirmatory analysis, the empirical validity of the DSM constructs underlying the diagnostic criteria for developmental disruptive behaviour disorders in Italian school-age children...
  6. ncbi Attention-deficit/hyperactivity disorder: a neuropsychiatric disorder with childhood onset
    A Zuddas
    Child Neurology and Psychiatry, Department of Neuroscience, University of Cagliari, Italy
    Eur J Paediatr Neurol 4:53-62. 2000
    ..Untreated, it predisposes children to psychiatric and social pathology later in life. Unlike other psychiatric disorders of childhood, it can be successfully treated...
  7. ncbi Teacher reports of ADHD symptoms in Italian children at the end of first grade
    Daniele Mugnaini
    A. Meyer Children's Hospital, Florence, Italy
    Eur Psychiatry 21:419-26. 2006
    ....
  8. ncbi The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles
    Robert D Oades
    Clinic for Child and Adolescent Psychiatry, University of Duisburg Essen, Germany
    Dev Sci 8:122-31. 2005
    ..Recent insights into the previously underestimated role of the NA system in the control of mesocortical DA function, and the frontal role in processing information are elaborated...
  9. ncbi A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD
    Jan K Buitelaar
    Department of Psychiatry, University Medical Center Nijmegen, 9101, 6500, HB Nijmegen, The Netherlands
    Eur Child Adolesc Psychiatry 13:249-57. 2004
    ..CONCLUSION: These open-label data, gathered in an international setting, add to our knowledge of the value of atomoxetine in treating ADHD symptoms, as well as its safety and tolerability...
  10. ncbi European clinical guidelines for hyperkinetic disorder -- first upgrade
    Eric Taylor
    Dept of Child and Adolescent Psychiatry, Institute of Psychiatry Kings College London, De Crespigny Park, London, SE5 8AF, UK
    Eur Child Adolesc Psychiatry 13:I7-30. 2004
    ..The validity of clinical guidelines changes over time, because new evidence-based knowledge and experience develop...
  11. ncbi [Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guidelines. Part 2: a quantitative evaluation of long-acting medications]
    Tobias Banaschewski
    Klinik fur Psychiatrie und Psychotherapie des Kindes und Jugendalters, Zentralinstitut fur Seelische Gesundheit, Mannheim
    Z Kinder Jugendpsychiatr Psychother 36:97-106; quiz 106-7. 2008
    ..Individual choices of therapy are necessary. (3) Both ATX and retarded-release stimulants should be available...
  12. ncbi [Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guideline. Part 1: overview and recommendations]
    Tobias Banaschewski
    Klinik fur Psychiatrie und Psychotherapie des Kindes und Jugendalters, Zentralinstitut fur Seelische Gesundheit, Mannheim
    Z Kinder Jugendpsychiatr Psychother 36:81-94; quiz 94-5. 2008
    ..3) Both ATX and extended-release stimulants should be available. In addition, detailed recommendations will be made with regard to the criteria to be applied in choosing a preparation for the individual patient...
  13. ncbi Contrasting deficits on executive functions between ADHD and reading disabled children
    Gian Marco Marzocchi
    Department of Psychology, University of Milan Bicocca, Italy
    J Child Psychol Psychiatry 49:543-52. 2008
    ..The object of this study was to analyze the executive functioning of children with attention deficit hyperactivity disorder (ADHD) or reading disability (RD) independent of their non-executive deficits...
  14. ncbi A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year
    Jan K Buitelaar
    University Medical Center St Radboud, Nijmegen, The Netherlands
    Biol Psychiatry 61:694-9. 2007
    ..The efficacy of atomoxetine in maintaining symptom response following 1 year of treatment was assessed in children and adolescents (n = 163) with DSM-IV defined attention-deficit/hyperactivity disorder (ADHD)...
  15. ncbi Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline
    Tobias Banaschewski
    Dept of Child and Adolescent Psychiatry Psychotherapy, University of Goettingen, Von Siebold Str 5, 37075 Goettingen, Germany
    Eur Child Adolesc Psychiatry 15:476-95. 2006
    ..Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made...
  16. ncbi The Italian preadolescent mental health project (PrISMA): rationale and methods
    Alessandra Frigerio
    Child Psychiatry Unit, Scientific Institute E Medea, Bosisio Parini LC, Italy
    Int J Methods Psychiatr Res 15:22-35. 2006
    ..The findings of this study are expected to allow an adequate planning of interventions for the prevention and the treatment of mental disorders in preadolescence as well as efficient health services...
  17. ncbi Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study
    Adriana Di Martino
    Institute for Pediatric Neuroscience, NYU Child Study Center, New York, NY, USA
    J Child Adolesc Psychopharmacol 14:207-18. 2004
    ..No significant adverse effects were observed in any of the 8 subjects. CONCLUSIONS: Administering a single MPH test dose may be useful in identifying children with PDD who may benefit from prolonged therapy...
  18. ncbi A comparison of North American versus non-North American ADHD study populations
    Jan K Buitelaar
    Dept of Psychiatry, Academic Centre for Child and Adolescent Psychiatry, University Medical Centre St Radboud, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    Eur Child Adolesc Psychiatry 15:177-81. 2006
    ..This supports the practice of generalizing results from treatment studies across geographies...
  19. ncbi Ontogeny of kainate receptor gene expression in the developing rat midbrain and striatum
    Vanessa Lilliu
    Child Neurology and Psychiatry, Department of Neuroscience, University of Cagliari, Italy
    Brain Res Mol Brain Res 104:1-10. 2002
    ....
  20. ncbi Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study
    David Michelson
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    J Am Acad Child Adolesc Psychiatry 43:896-904. 2004
    ..Attention-deficit/hyperactivity disorder (ADHD) is typically treated over extended periods; however, few placebo-controlled, long-term studies of efficacy have been reported...
  21. ncbi Italian attention-deficit/hyperactivity disorder registry
    Pietro Panei
    Pediatrics 114:514. 2004